A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
Completed
Hoffmann-La Roche
Phase 4
2005-08-01
The purpose of this randomized, double-blind, placebo-controlled study is to estimate the
effect of oral ibandronate sodium (Boniva) taken once monthly versus placebo on bone quality
and strength at the proximal femur at one year.
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
Completed
Hoffmann-La Roche
Phase 4
2006-02-01
This study will determine the rapidity of suppression of the bone resorption marker sCTX in
post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated.
Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with
vitamin D and calcium supplementation. The anticipated time on study treatment is
approximately 7 months, and the target sample size is <100 individuals.
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Completed
Hoffmann-La Roche
Phase 4
2006-05-01
This 2 arm crossover study will evaluate patient reported preference for either once monthly
Boniva (150mg p.o.) or once weekly risedronate (35mg p.o.). Patients with post-menopausal
osteoporosis will be randomized to receive Boniva for 3 calendar months or risedronate for 12
weeks; they will then cross over to receive the alternative treatment for a further 12
weeks/3 months. The anticipated time on study treatment is 3-12 months, and the target sample
size is 100-500 individuals.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
